GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.

Junshi’s PD-1 Antibody Meets Endpoint In Phase 3 Lung Cancer Trial

by Joy Lin
Share To

Junshi Biosciences’ toripalimab has met its primary endpoint of event-free survival (EFS) in the Neotorch Phase 3 Study as a perioperative treatment for operable non-small cell lung cancer (NSCLC). 

In Neotorch, the PD-1 monoclonal antibody is combined with platinum-containing doublet chemotherapy and administered around the time of the surgery.  

Based on the positive data, Junshi said it will discuss with regulatory authorities to support a supplemental New Drug Application (NDA) in the near future.  

Related Article: JPM23: Partnerships Take off From JP Morgan Healthcare Conference 2023 Day One

First Positive EFS in Phase 3 on Perioperative I-O for Lung Cancer 

Clinical trials have shown that immunotherapy can significantly improve the overall survival of patients with advanced NSCLC. However, research on operable NSCLC is relatively recent and focused on preoperative neoadjuvant or postoperative adjuvant therapy. Perioperative I-O therapy covering the whole process, including pre- and post-surgery, is expected to be a better treatment model for patients.

By inhibiting PD-1 on T-cells, torapalimab allows the immune cells to ignore the “don’t-eat-me” signal, PD-L1, which cancerous cells often express. 

Neotorch is the world’s first Phase 3 study of perioperative immunotherapy for lung cancer with a positive EFS result, said Junshi. Besides EFS, the trial will also assess the major pathological remission rate (MPR) rate as the other primary endpoint. Secondary endpoints include pathological complete remission rate (pCR rate), EFS as assessed by Independent Review Committee (IRC) and disease-free survival (DFS), overall survival (OS). 

On the safety front, the data on torapalimab aligns with known risks, with no new safety signals identified. 

Torapalimab is approved for six indications in China, ranging from melanoma to NSCLC. In the US, the FDA is reviewing the Biologics License Application (BLA) resubmission for toripalimab in combination with gemcitabine and cisplatin as first-line treatment in advanced recurrent or metastatic nasopharyngeal (NPC) and for toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy.

In Europe, the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA)for torapalimab in combination with platinum-containing chemotherapy for first-line advanced NPC.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Illumina’s IVD Biomarker Test Becomes the First FDA-approved Pan-cancer Companion Diagnostics Kit
2024-09-11
R&D
Merck’s KEYTRUDA Fails in Early-Stage Lung and Skin Cancer Trials, Ends Two Phase 3 Studies
2024-08-30
ASCO Breakthrough 2024: Key Advances in the NSCLC Landscape with First-line Treatment Selpercatinib Trial Updates
2024-08-08
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
Scroll to Top